STOCK TITAN

Molecular Templates, Inc. - $MTEM STOCK NEWS

Welcome to our dedicated page for Molecular Templates news (Ticker: $MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Molecular Templates's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Molecular Templates's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.18%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
Molecular Templates, Inc.

Nasdaq:MTEM

MTEM Rankings

MTEM Stock Data

10.80M
3.28M
3.96%
58.79%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About MTEM

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.